New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
04:55 EDTBCR, BCR, ISIS, ISIS, TRVN, TRVN, SGEN, SGEN, ONCS, ONCS, KBIO, KBIO, GNMK, GNMK, LXRX, LXRX, ACAD, ACAD, EXAM, EXAMNeedham to hold a conference
Life Sciences Conference is being held in New York on April 8-9.
News For BCR;ACAD;LXRX;GNMK;KBIO;ONCS;SGEN;TRVN;ISIS;EXAM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 20, 2015
06:32 EDTBCRC.R. Bard upgraded to Neutral from Underweight at JPMorgan
JPMorgan upgraded C.R. Bard to Neutral on expectations drug-coated balloons growth in the U.S. is likely to exceed consensus expectations. The firm raised its price target for shares to $178 from $162.
January 15, 2015
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information
January 14, 2015
07:05 EDTISISIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
17:13 EDTBCRC.R. Bard wins favorable patent ruling over W.L. Gore & Associates
Subscribe for More Information
14:44 EDTACADACADIA says Nuplazid NDA submission planned for 1Q15
Subscribe for More Information
08:29 EDTONCSOncoSec to host a symposium
Subscribe for More Information
January 12, 2015
16:13 EDTGNMKGenMark sees Q4 revenue $9.8M, consensus $8.3M
Subscribe for More Information
08:15 EDTSGENSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
06:14 EDTONCSOncoSec plans to initiate pilot study in triple negative breast cancer
OncoSec plans to initiate a pilot study to assess IL-12 ImmunoPulse in patients with Triple Negative Breast Cancer. The study will be conducted at Stanford University with Melinda L. Telli, MD, serving as lead investigator. This pilot study is designed to assess whether IL-12 ImmunoPulse increases TNBC tumor immunogenicity by driving a pro-inflammatory cascade of events that leads to increases in cytotoxic tumor-infiltrating lymphocytes. The presence and number of TILs is thought to be a key requirement for promoting the anti-tumor activity of antibodies like anti-PD-1/PD-L1. By driving cytotoxic immune cells into the tumor, IL-12 ImmunoPulse may be an ideal candidate to combine with checkpoint blockade therapies which reported some activity in TNBC.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use